

NTAP Crosswalk-FY 2028 Program

(PRA Process Note 1: For this redlined crosswalk, comments have been added to indicate the application flow pattern (e.g., YES/NO question sequences). Corresponding letters and numbers have been added to the sections and questions for ease of reference in discussion of the application. The comment bubbles, letters, and numbers do not appear in the application).

Application Section	Application Language	Modifications	Burden	Revised Application Language
Application Setup	<p><i>Let's set up your NTAP application</i> You will not be able to change these selections in the application.</p> <p>Select which NTAP pathway you are applying under. For additional information on the alternative pathways for transformative new devices and certain antimicrobial products, please refer to the <i>NTAP Criteria and Pathways</i> information above.</p> <ul style="list-style-type: none"> • Alternative • Traditional 	Simple text edit for accuracy.	No change	<p>Section: NTAP Application Setup</p> <p><i>Let's set up your NTAP application</i> You will not be able to change this selection.</p> <p>Select which NTAP pathway you are applying under. For additional information on the alternative pathways for transformative new devices and certain antimicrobial products, please refer to the <i>NTAP Criteria and Pathways</i> information above.</p> <ul style="list-style-type: none"> • Alternative • Traditional

Application Section	Application Language	Modifications	Burden	Revised Application Language
Disclaimer	<p style="text-align: center;"><u>Disclaimer</u></p> <p>All content submitted as part of this application may be made public unless otherwise noted below. Please see the FY 2023 IPPS final rule (87 FR 48986-48990) for a discussion of the policy to publicly post NTAP applications.</p> <ul style="list-style-type: none"> Information that should not be made public is not taken into consideration when determining whether a technology meets the NTAP criteria. Throughout this application, “made public” refers to either posting application materials publicly or including information from an application in our discussion in the Federal Register. If you would like to include information that should not be made public as part of your application, please refer to the “Additional Application Information - CONFIDENTIAL” section on the summary page at the end of the application. <i>We also note that we will not make public any contact information or dates included in the “FDA Info” section related to FDA applications that are not yet approved or cleared, as indicated in the application.</i> <p>Please note that the following application sections are <i>not included in the public application posting. However, some of the information submitted within the following sections may still be included in the proposed or final rules, as indicated:</i></p> <p>Cost</p> <ul style="list-style-type: none"> For <i>alternative pathway applications</i>, information in this section may be included in the proposed and final rules. The <i>cost</i> of the technology will <i>be included in the proposed and final rules.</i> For <i>traditional pathway applications</i>, information in this section may be included in the proposed and final rules. The <i>cost of the technology will be only be included in the final rule (for technologies approved for NTAP).</i> <p>Volume</p> <ul style="list-style-type: none"> The information in this section will only be included in the final rule (for technologies approved for NTAP). <p>Cost Criterion</p> <ul style="list-style-type: none"> The <i>NTAP Cost Criterion Codes and MS-DRGs worksheet will be publicly posted.</i> <p><i>Other information in this section may be included in the proposed and final rules. Please note that the numerical value of any charges in this section will not be made public, with the exception of column S (Final Inflated Case Weighted Standardized Charge Per Case).</i></p> <p>Please note that any data provided in this application may become subject to disclosure where required by law. Where CMS has indicated that information won’t be made public, CMS will attempt, to the extent allowed by law, to keep that information protected from public view.</p> <p>Please also note that application tracking forms will be posted on the CMS website shortly after the application deadline. Please refer to the <i>NTAP Tracking Form Info</i> above for additional information.</p> <p><input type="checkbox"/> I certify that I have been duly authorized to submit this application on behalf of the applicant. I acknowledge and agree that I have read the Disclaimer and understand that all of the information in this application may be made public, unless otherwise noted or included in the “Additional</p>	<p>We have reorganized this segment to simplify:</p> <p>We’ve moved FDA info into its own bulleted section, and grouped Cost and Volume sections together as they appear in the application.</p> <p>Text changes: We’ve made edits to better describe the full rule name, use (broader) ‘market authorized language’ for FDA status, and update what information is shared publicly (additional cost criterion information is now shared online, rather than in the NPRM drafts).</p> <p>Remaining edits clarify columns referenced in the cost criterion and call out further details about public application posting exclusions (that already appear throughout the application).</p>	No change	<p style="text-align: center;"><u>Disclaimer</u></p> <p>All content submitted as part of this application may be made public unless otherwise noted below. Please see the FY 2023 IPPS/LTCH PPS final rule (87 FR 48986-48990) for a discussion of the policy to publicly post NTAP applications.</p> <p>Information that should not be made public is not taken into consideration when determining whether a technology meets the NTAP criteria. Throughout this application, “made public” refers to either posting application materials publicly or including information from an application in our discussion in the Federal Register. If you would like to include information that should not be made public as part of your application, please refer to the “Additional Application Information - CONFIDENTIAL” section on the summary page at the end of the application.</p> <p>Please note the following information about the sections indicated:</p> <p>FDA Info</p> <ul style="list-style-type: none"> <i>We will not make public any contact information or dates included in the “FDA Info” section related to FDA applications for technologies that are not FDA market authorized.</i> <p>Cost and Volume</p> <ul style="list-style-type: none"> <i>This section is not included in the public application posting. However, for alternative pathway applications, cost information may be included in the proposed and final rules.</i> <i>For traditional pathway applications, information in this section may be included in the proposed and final rules. The cost of the technology will only be included in the final rule (for technologies approved for NTAP).</i> <p>Cost Criterion</p> <ul style="list-style-type: none"> <i>This section will be included in the public application posting, except for the NTAP Cost Analysis spreadsheet. However, information provided in the spreadsheet may be included in the proposed and final rules.</i> <i>The numerical value of any charges in this section will not be made public, with the exception of the Case Weighted Threshold (Column E) and the Final Inflated Case Weighted Standardized Charge Per Case (Column S).</i> <p>Additional details about public application posting exclusions may be found in the applicable application sections.</p> <p>Please note that any data provided in this application may become subject to disclosure where required by law. Where CMS has indicated that information won’t be made public, CMS will attempt, to the extent allowed by law, to keep that information protected from public view.</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	Application Information - CONFIDENTIAL” section.			
Disclaimer (only displays for traditional applications)	<p>Copyrighted Information: For supporting evidence uploaded in the Substantial Clinical Improvement (SCI) section of the application, you will be asked if the applicant does not have the appropriate license or right to release each document to the public. At the end of the SCI section, you will be asked to represent and warrant that the applicant owns the copyright or otherwise has the appropriate license to make any copyrighted material releasable to the public, with the exception of those materials for which the applicant indicates otherwise. Please be sure to select the appropriate checkboxes as you go through the SCI section to provide a representation of whether the files can be included in the public posting. You will also be asked to provide citations for the materials, and CMS will post those citations publicly. Documents that cannot be publicly posted will still be considered by CMS and may be summarized in the proposed rule, and the summary information provided by the applicant will be posted publicly.</p> <p><input type="checkbox"/> I certify that I have been duly authorized by the applicant to sign this acknowledgement on behalf of the applicant. I acknowledge and agree that I have read this information regarding copyrighted information and understand that I will be required to represent and warrant that, except for studies for which I indicate otherwise, the applicant owns the copyright or otherwise has the appropriate license to make the studies included in the SCI section available to the public. I understand that CMS may post publicly any study for which I indicate that the applicant owns the copyright or otherwise has the appropriate license to make it public.</p>	No change	No change	<p>Copyrighted Information: For supporting evidence uploaded in the Substantial Clinical Improvement (SCI) section of the application, you will be asked if the applicant does not have the appropriate license or right to release each document to the public. At the end of the SCI section, you will be asked to represent and warrant that the applicant owns the copyright or otherwise has the appropriate license to make any copyrighted material releasable to the public, with the exception of those materials for which the applicant indicates otherwise. Please be sure to select the appropriate checkboxes as you go through the SCI section to provide a representation of whether the files can be included in the public posting. You will also be asked to provide citations for the materials, and CMS will post those citations publicly. Documents that cannot be publicly posted will still be considered by CMS and may be summarized in the proposed rule, and the summary information provided by the applicant will be posted publicly.</p> <p><input type="checkbox"/> I certify that I have been duly authorized by the applicant to sign this acknowledgement on behalf of the applicant. I acknowledge and agree that I have read this information regarding copyrighted information and understand that I will be required to represent and warrant that, except for studies for which I indicate otherwise, the applicant owns the copyright or otherwise has the appropriate license to make the studies included in the SCI section available to the public. I understand that CMS may post publicly any study for which I indicate that the applicant owns the copyright or otherwise has the appropriate license to make it public.</p>
Contact Information	<p>Contact Information <i>Info: The information in this section (A) will not be made public, except the name of the party requesting the NTAP. Please note that the MEARIS website can only be accessed by individuals who are located in the US.</i></p> <ul style="list-style-type: none"> ▪ Who is the party requesting the NTAP? (e.g. manufacturer, distributor, healthcare organization/entity) Provide a contact for the applicant. Applicant Contact: <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • Phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country • Mailing Address 1 • Mailing Address 2 (optional) 	We added the TM symbol for MEARIS TM , clarified that we’re looking for the name of the manufacturer (vs. whether it is a manufacturer), and simplified the applicant types to eliminate the types that are not typically used (who could still opt for ‘other’ if they were to apply).	No change	<p>A. Contact Information <i>Info: The information in this section (A) will not be made public, except the name of the party requesting the NTAP. Please note that the MEARISTM website can only be accessed by individuals who are located in the US.</i></p> <ul style="list-style-type: none"> 1. Who is the party requesting the NTAP? (e.g. name of the manufacturer, distributor, healthcare organization/entity) Provide a contact for the applicant. Applicant Contact: <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • Phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country • Mailing Address 1 • Mailing Address 2 (optional)

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> • City • State • Zip • Applicant Type (selections): <ul style="list-style-type: none"> ○ Distributor, Manufacturer, Healthcare Organization, Other (explain) 			<ul style="list-style-type: none"> • City • State • Zip • Applicant Type (selections): <ul style="list-style-type: none"> ○ Manufacturer, Other (explain)
Contact Information	<p>Who is the primary contact?</p> <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • US phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country • Mailing Address 1 • Mailing Address 2 (optional) • City • State • Zip • Relationship (selections): <ul style="list-style-type: none"> ○ Consultant, Manufacturer, Other (explain) 	Updates to the primary contact field allow for auto-population of the primary contact field, if the information is the same as the applicant contact. The country is also auto-populated, to ensure at least one U.S. based contact is provided.	Change in burden is minor (reduction)	<p>2. Who is the primary contact? <input type="checkbox"/> Select if this is the same as the Applicant Contact and the fields will auto-populate.</p> <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • US phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country: United States • Mailing Address 1 • Mailing Address 2 (optional) • City • State • Zip • Relationship (selections): <ul style="list-style-type: none"> ○ Consultant, Manufacturer, Other (explain)
Contact Information	<p>Who is the secondary contact?</p> <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • US phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country • Mailing Address 1 • Mailing Address 2 (optional) • City • State • Zip • Relationship (selections): <ul style="list-style-type: none"> ○ Consultant, Manufacturer, Other (explain) 	Same as before	No change	<p>3. Who is the secondary contact?</p> <ul style="list-style-type: none"> • First Name • Middle Name (optional) • Last Name • US phone number • Organization • Occupation / Job Title • Extension (optional) • Email Address • Country • Mailing Address 1 • Mailing Address 2 (optional) • City • State • Zip • Relationship (selections): <ul style="list-style-type: none"> ○ Consultant, Manufacturer, Other (explain)

Application Section	Application Language	Modifications	Burden	Revised Application Language
Technology Info	<p>Technology Info</p> <p><i>Note: If one of the name fields do not apply or is TBD, please leave the field blank.</i></p> <p>General Information</p> <ul style="list-style-type: none"> • Applicant • Trade Name • Generic Name • Please provide a brief (1-2 sentence) description of the technology. 	The applicant information will now auto-populate based on the prior question.	Change in burden is very minor (reduction)	<p>B. Technology Info</p> <p><i>Note: If one of the name fields do not apply or is TBD, please leave the field blank.</i></p> <p>1. General Information</p> <ol style="list-style-type: none"> Applicant Trade Name Generic Name Please provide a brief (1-2 sentence) description of the technology.
Technology Info	<p>Describe the technology in detail, using general terminology</p> <ul style="list-style-type: none"> • What is the technology? • What does the technology do? • How is the technology used? <p>Upload relevant descriptive booklets, brochures, package inserts, or other supporting materials as needed (optional). <i>Note: Please note that attachments uploaded in this section will not be included in the public posting. Please avoid referring to any attachments in the responses provided in this section. If using references, please use in-text citations rather than footnote numbering.</i></p>	No change	No change	<p>2. Describe the technology in detail, using general terminology</p> <ul style="list-style-type: none"> • What is the technology? • What does the technology do? • How is the technology used? <p>Upload relevant descriptive booklets, brochures, package inserts, or other supporting materials as needed (optional). <i>Note: Please note that attachments uploaded in this section will not be included in the public posting. Please avoid referring to any attachments in the responses provided in this section. If using references, please use in-text citations rather than footnote numbering.</i></p>
Technology Info	<p>Additional Technology Information</p> <ul style="list-style-type: none"> ○ Is there an Investigational Device Exemption (IDE) number from the FDA assigned to the technology? (Yes/No) <ul style="list-style-type: none"> ○ IF YES: IDE Number ○ If the technology is a device, what class is assigned to the technology? (Class I, II, III, unclassified, N/A) ○ If the technology is a drug, is this a drug that can only be administered orally? (Yes/No N/A) • If the technology is a drug, what is the drug's dosage/administration information when used in the inpatient setting? Please clearly indicate the average total dose per inpatient stay. • Has the technology ever been the subject of a recall or subject to any bulletins and/or letters issued by the FDA regarding the safety of the technology? (Yes*/No) <ul style="list-style-type: none"> ○ IF YES: Provide specific details regarding the recall, bulletins 	<p>Minor revisions to eliminate questions that we determined are not necessary.</p> <p>Additional minor revisions to existing question text to capture detail for all technologies.</p>	Change in burden is neutral (very minor reduction + very minor increase)	<p>3. Additional Technology Information</p> <ol style="list-style-type: none"> What is the technology's dosage/administration information when used in the inpatient setting? Please clearly indicate the average total dose/use per inpatient stay. Has the technology ever been the subject of a recall or subject to any bulletins and/or letters issued by the FDA regarding the safety of the technology? (Yes/No) <ul style="list-style-type: none"> ○ IF YES: Provide specific details regarding the recall, bulletins and/or letters issued by the FDA. <p>Please upload the recall, bulletins, or other documentation (REQUIRED IF YES IS SELECTED)</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p>and/or letters issued by the FDA.</p> <ul style="list-style-type: none"> Please upload the recall, bulletins, or other documentation (REQUIRED IF YES IS SELECTED) 			
Technology Info	<p>Have you completed any outpatient pass through applications for this technology? (Yes/No) IF NO, skip to question 7 IF YES: Additional Technology Information Was this application submitted using MEARIS™? (Yes/No) IF YES, provide application type (Device OR Drug/Biological Pass through)</p> <ul style="list-style-type: none"> Application Confirmation Number Provide Details (text box 3000 characters) <p>IF NO, provide application type (Device OR Drug/Biological Pass through)</p> <ul style="list-style-type: none"> Submission Date Provide Details 	Minor edits to remove limits on text box.	No change	<p>4. Have you completed any outpatient pass through applications for this technology? (Yes/No) IF YES: a. Additional Technology Information Was this application submitted using MEARIS™? (Yes/No) IF YES, provide application type (Device OR Drug/Biological Pass through)</p> <ul style="list-style-type: none"> Application Confirmation Number Provide Details <p>IF NO, provide application type (Device OR Drug/Biological Pass through)</p> <ul style="list-style-type: none"> Submission Date Provide Details
Alternative Pathway Designation (only displays for Alternative Pathway applications)	<p>Alternative Pathway Has the technology already received a Breakthrough Device/QIDP designation or LPAD approval from FDA for the indication relevant to this application? (YES/NO) <i>Info: For additional information on the alternative pathways for transformative new devices and certain antimicrobial products, please refer to the NTAP Criteria and Pathways information above.</i></p> <p>IF YES: Alternative Pathway Designation</p> <p><i>Note: Only the marketing authorization indication in the FDA section of this application that corresponds to the Breakthrough Device/QIDP/LPAD designation is eligible for NTAP.</i></p> <ul style="list-style-type: none"> Please provide details about the relevant designation/approval. Include the date received and the full Breakthrough Device/QIDP designation or approved LPAD indication on the FDA letter. Upload a copy of the Breakthrough Device/QIDP designation or LPAD approval letter. If the indication in the FDA section of this application does not match the Breakthrough Device/QIDP/LPAD designation in the attached letter, please provide an explanation. 	We've made minor edits to add language in the title (Designation), and we've removed the requirement for inclusion of the date, as we determined it to be unnecessary for our evaluation (it's available on the letter which is uploaded by applicants). We also added an 'info:' tag to indicate we're providing our commentary (about dates not being made public) as information for the applicant.	No measurable change	<p>C. Alternative Pathway Designation 1. Has the technology already received a Breakthrough Device/QIDP designation or LPAD approval from FDA for the indication relevant to this application? (YES/NO) <i>Info: For additional information on the alternative pathways for transformative new devices and certain antimicrobial products, please refer to the NTAP Criteria and Pathways information above.</i></p> <p>IF YES: a. Alternative Pathway Designation</p> <p><i>Note: Only the marketing authorization indication in the FDA section of this application that corresponds to the Breakthrough Device/QIDP/LPAD designation is eligible for NTAP.</i></p> <ul style="list-style-type: none"> Please provide details about the relevant designation/approval. Include the full Breakthrough Device/QIDP designation or approved LPAD indication on the FDA letter. Upload a copy of the Breakthrough Device/QIDP designation or LPAD approval letter. If the indication in the FDA section of this application does not match the Breakthrough Device/QIDP/LPAD designation in the attached letter, please provide an explanation. If the name of the technology in this application does not match the technology name in the attached letter, please provide an explanation.

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> o If the name of the technology in this application does not match the technology name in the attached letter, please provide an explanation. o If the technology was granted Breakthrough Device designation, please indicate if the device that is the subject of this application is the same device that was granted the Breakthrough Device designation: (select one) <ul style="list-style-type: none"> -Yes, this is the designated device (explanation optional) -No, this is not the designated device (explanation required) -Does not apply <p>IF NO: Alternative Pathway Designation <i>Dates included in this response will not be made public.</i> Provide details regarding the Alternative Pathway designation and its status including the type (Breakthrough Device/QIDP/LPAD) and date of the designation request submission to FDA, the date of anticipated approval of the designation request, and the designation indication. <i>Note: Only the marketing authorization indication in the FDA section of this application that corresponds to the Breakthrough Device/QIDP/LPAD designation is eligible for NTAP</i></p>			<ul style="list-style-type: none"> o If the technology was granted Breakthrough Device designation, please indicate if the device that is the subject of this application is the same device that was granted the Breakthrough Device designation: (select one) <ul style="list-style-type: none"> -Yes, this is the designated device (explanation optional) -No, this is not the designated device (explanation required) -Does not apply <p>IF NO: b. Alternative Pathway Designation <i>Info: Dates included in this response will not be made public.</i> Provide details regarding the Alternative Pathway designation and its status including the type (Breakthrough Device/QIDP/LPAD) and date of the designation request submission to FDA, the date of anticipated approval of the designation request, and the designation indication. <i>Note: Only the marketing authorization indication in the FDA section of this application that corresponds to the Breakthrough Device/QIDP/LPAD designation is eligible for NTAP.</i></p>
FDA Info	<p><u>FDA Information</u></p> <p>FDA Status</p> <ul style="list-style-type: none"> o What is the indication for the technology for which the applicant is submitting an NTAP application? o List if the technology has received any designations from FDA or if it is being considered under any particular pathways by FDA such as Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, etc. for this indication (optional) <p>Has the technology already received marketing authorization from the Food and Drug Administration (FDA) for the indication relevant to this application? <i>Info: To be considered for NTAP for FY 2025, alternative pathway devices (Breakthrough Devices) will need to receive FDA approval or clearance before 5/1/2024. Alternative pathway drugs (QIDP/LPAD) are eligible for</i></p>	<p>Minor edits:</p> <p>The title has been changed to 'FDA Info' from FDA Information, to reduce the footprint on the header tab. We also determined that we can eliminate one question about designations. The marketing authorization question and answer choices are re-worded for clarity. Dates are updated annually.</p>	<p>Change in burden is minor (reduction).</p>	<p><u>D. FDA Info</u></p> <p>1. FDA Status</p> <ul style="list-style-type: none"> o What is the indication for the technology for which the applicant is submitting an NTAP application? <p>2. Has the technology already received marketing authorization from FDA for the indication that is the subject of this NTAP application? <i>Info: To be considered for NTAP for FY 2027, alternative pathway devices (Breakthrough Devices) will need to receive FDA approval or clearance before 5/1/2026. Alternative pathway drugs (QIDP/LPAD) are eligible for conditional approval if they do not receive FDA marketing authorization before 7/1/2026. Technologies conditionally approved for FY 2027 under this pathway will need to receive FDA approval or clearance before 7/1/2027 in order to receive NTAP.</i></p> <p>Choose 1:</p> <ul style="list-style-type: none"> • Yes

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p><i>conditional approval if they do not receive FDA marketing authorization before 7/1/2024. Technologies conditionally approved for FY 2025 under this pathway will need to receive FDA approval or clearance before 7/1/2025 in order to receive NTAP.</i></p> <p>Choose 1:</p> <ul style="list-style-type: none"> • Yes • No, but the marketing authorization request has been accepted/filed by FDA and approval/clearance is expected before the FDA deadline (May 1, 2024 for Breakthrough Devices / July 1, 2025 for QIDP/LPAD) <p>(for traditional pathway application, the second bullet simply reads, “No, but marketing authorization is expected by the FDA deadline ([date])”</p>			<ul style="list-style-type: none"> • No, but the marketing authorization request has been accepted/filed by FDA and approval/clearance is expected before the deadline for FDA marketing authorization (May 1, 2026 for Breakthrough Devices / July 1, 2027 for QIDP/LPAD) <p>(for traditional pathway application, the second bullet simply reads, “No, but marketing authorization is expected by the FDA deadline ([date])”</p>
FDA Info	<p>Yes Sequence</p> <p>FDA Approval/Clearance Details</p> <ul style="list-style-type: none"> ○ What is the type of the FDA application? <i>Examples: Premarket Notification 510(k), De Novo Classification, Premarket Approval Application (PMA), Humanitarian Device Exemption (HDE), New Drug Application (NDA), Biologic License Application (BLA)</i> <input type="checkbox"/> Checkbox: “Select if this is a 510(k) FDA application” ○ What is the date of FDA approval? ○ Upload FDA approval letter (required). <i>Note: Please note that attachments uploaded in this section will not be included in the public posting. Please avoid referring to any attachments in the responses provided in this section.</i> <ul style="list-style-type: none"> • Summarize the supporting information contained in the FDA approval letter. 	<p>Minor edits:</p> <p>FDA status of ‘clearance’ has been added as a technical clarification for accuracy.</p>	No change	<p>3.a. Yes Sequence</p> <p>FDA Approval/Clearance Details</p> <ul style="list-style-type: none"> ○ What is the type of the FDA application? <i>Examples: Premarket Notification 510(k), De Novo Classification, Premarket Approval Application (PMA), Humanitarian Device Exemption (HDE), New Drug Application (NDA), Biologic License Application (BLA)</i> <input type="checkbox"/> Checkbox: “Select if this is a 510(k) FDA application” ○ What is the date of FDA approval/clearance? ○ Upload FDA approval/clearance letter (required). <i>Note: Please note that attachments uploaded in this section will not be included in the public posting. Please avoid referring to any attachments in the responses provided in this section.</i> <ul style="list-style-type: none"> • Summarize the supporting information contained in the FDA approval/clearance letter.
FDA Info	<p>No Sequence</p> <p>FDA Submission Details</p> <p><i>Info: All of the FDA dates entered in this question will not be made public.</i></p> <ul style="list-style-type: none"> ○ What is the date of FDA submission? ○ What is the type of the FDA application? <i>Examples: Premarket Notification 510(k), De Novo Classification, Premarket Approval Application (PMA), Humanitarian Device Exemption (HDE), New Drug Application (NDA), Biologic License</i> 	<p>Minor edits:</p> <p>Minor changes to the “Info” language have been made for clarity. Further clarifications have been made to instructions to clarify the ‘complete and active’ application requirements, and documentation required to</p>	No change	<p>3.b. No Sequence</p> <p>FDA Submission Details</p> <p><i>Info: FDA dates entered in this question related to FDA applications for technologies that are not FDA market authorized will not be made public.</i></p> <ul style="list-style-type: none"> ○ What is the date of FDA submission? ○ What is the type of the FDA application? <i>Examples: Premarket Notification 510(k), De Novo Classification, Premarket Approval Application (PMA), Humanitarian Device Exemption (HDE), New Drug Application (NDA), Biologic License Application (BLA)</i> <input type="checkbox"/> Checkbox: “Select if this is a 510(k) FDA application”

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p><i>Application (BLA)</i></p> <p><input type="checkbox"/> Checkbox: “Select if this is a 510(k) FDA application”</p> <ul style="list-style-type: none"> ○ What is the expected action date from FDA? (eg PDUFA date/MDUFA goal date) ○ Provide additional information about your FDA application. Include the review status of your application with FDA For example, indicate whether it is accepted/ filed and under review, on hold, denied, pending reapplication or submission of additional information, etc. ○ Note: <i>As finalized in the FY 2024 IPPS final rule, technologies must be under complete and active review by FDA at the time of NTAP application submission in order to be eligible for consideration. For additional information regarding this NTAP eligibility requirement, please see the regulations at § 412.87(e) and the FY 2024 IPPS final rule.</i> ○ Upload the FDA acceptance or filing letter for this submission. Note: <i>As finalized in the FY 2024 IPPS final rule, we are requiring the relevant acceptance letter (such as for 510k applications or De Novo Classification requests) or filing letter (such as for PMA, BLA, or NDA applications) from FDA which indicates that FDA has determined that the application is sufficiently complete to allow for substantive review by FDA.</i> <p>Please provide additional information regarding the 510(k) clearance</p> <ul style="list-style-type: none"> ○ List the predicate device(s) for the technology. ○ Describe any differences between the devices. 	substantiate FDA status.		<ul style="list-style-type: none"> ○ What is the expected action date from FDA? (eg PDUFA date/MDUFA goal date) ○ Provide additional information about your FDA application. Include the review status of your application with FDA. For example, indicate whether it is accepted/ filed and under review, on hold, denied, pending reapplication or submission of additional information, etc. Note: <i>As finalized in the FY 2024 and FY 2025 IPPS/LTCH PPS final rules, technologies must be the subject of a complete and active FDA marketing authorization request (that is, not withdrawn, the subject of a Complete Response Letter, or the subject of a final decision from FDA to refuse to approve the application) at the time of NTAP application submission in order to be eligible for consideration. For additional information regarding this NTAP eligibility requirement, please see the regulations at § 412.87(e) and the FY 2024 and FY 2025 IPPS/LTCH PPS final rules.</i> ○ Upload the documentation of FDA acceptance (for 510k applications or De Novo Classification requests) or filing (for PMA, BLA, or NDA applications) for this submission. Note: <i>As finalized in the FY 2024 IPPS/LTCH PPS final rule, at the time of NTAP application submission, applicants are required to provide documentation (consistent with the type of FDA marketing authorization application the applicant has submitted to FDA) which demonstrates that FDA has determined that the application is sufficiently complete to allow for substantive review by FDA.</i> <ul style="list-style-type: none"> • For 510k applications or De Novo Classification requests, upload documentation of FDA acceptance of the request • For a PMA, NDA, or BLA, upload documentation of FDA filing of the request <p><i>If applicants have questions about which documentation should be submitted, an inquiry may be submitted to CMS at NewTech@cms.hhs.gov.</i></p> <p>Please provide additional information regarding the 510(k) clearance</p> <ul style="list-style-type: none"> ○ List the predicate device(s) for the technology. ○ Describe any differences between the devices.
FDA Info	<p><i>The information provided below will not be made public.</i></p> <ul style="list-style-type: none"> ○ Please provide contact information for the FDA reviewer most knowledgeable about your application. ○ First Name ○ Middle Name (optional) ○ Last Name ○ US Phone Number ○ Email Address 	We’ve made very minor edits to be more precise.	No change	<p>4. FDA Contact <i>The information in this question will not be made public.</i></p> <p>Please provide contact information for the FDA reviewer most knowledgeable about your application.</p> <ul style="list-style-type: none"> ○ First Name ○ Middle Name (optional) ○ Last Name ○ US Phone Number ○ Email Address
FDA Info	Market Availability	Minor edits have been made to consolidate yes/no	No change	<p>5. Market Availability</p> <ul style="list-style-type: none"> ○ Was this technology available on the market immediately after FDA marketing

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p>o Do you anticipate that this technology will be available on the market immediately after FDA approval? (Yes/No) IF YES, <i>skip to “Additional FDA Information” section</i> IF NO:</p> <ul style="list-style-type: none"> • Please describe the reason for the delay in market availability. • When did the technology become available for sale, or when do you anticipate the technology becoming available? <p>IF NO:</p> <p>o Reason for the delay Please describe the reason for the delay in market availability and provide the anticipated release date.</p>	sequence to simplify. Wording was also edited for technical accuracy.		authorization OR if not yet approved/cleared, do you anticipate that it will be available immediately after FDA marketing authorization)? (Yes/No) IF NO: <ul style="list-style-type: none"> • Please describe the reason for the delay in market availability. • When did the technology become available for sale, or when do you anticipate the technology becoming available?
FDA Info	Additional FDA Information Please describe any previous US approvals/clearances for this technology. Include any additional approvals (e.g. Pre-Market Approval, HDE or HUD approval, expanded access approval) the technology received prior to submission of this application and/or is currently seeking, including approvals for other indications or clearances for other versions of this technology. CMS recommends a timeline if the technology has received multiple types of approvals from the FDA.	Minor edit to eliminate “the” in front of FDA (per FDA preference).	No change	6. Additional FDA Information Please describe any previous US approvals/clearances for this technology. Include any additional approvals (e.g. Pre-Market Approval, HDE or HUD approval, expanded access approval) the technology received prior to submission of this application and/or is currently seeking, including approvals for other indications or clearances for other versions of this technology. CMS recommends a timeline if the technology has received multiple types of approvals from FDA.
Coding and MS-DRGs	Coding and MS-DRGs <i>If the technology/device utilized in the performance of a procedure/service or the administration of a drug/therapeutic agent were to receive add-on payment status approval, it would need to be distinctly identifiable by a unique code, such as ICD-10-PCS procedure code(s), with or without ICD-10-CM diagnosis codes, on the claim in order to receive the add-on payment. The ICD-10 Coordination and Maintenance (C&M) Committee is responsible for approving coding changes, developing errata, addenda, and other modifications. Requests for coding changes are submitted to the committee for discussion at either the Spring or Fall C&M meeting. If any coding changes are necessary to distinctly identify your technology by ICD-10-CM diagnosis and/or ICD-10-PCS procedure code(s), you MUST separately contact the ICD-10 C&M Committee to submit a code request. For more details, including the deadlines to submit code requests, refer to the New/Revised ICD-10-PCS Procedure Codes Requests and ICD-10 Coordination and Maintenance Committee for diagnosis code requests.</i>	We have removed language regarding the Spring or Fall C&M meeting, in coordination with the team that manages those meetings.	No change	E. Coding and MS-DRGs <i>If the technology/device utilized in the performance of a procedure/service or the administration of a drug/therapeutic agent were to receive add-on payment status approval, it would need to be distinctly identifiable by a unique code, such as ICD-10-PCS procedure code(s), with or without ICD-10-CM diagnosis codes, on the claim in order to receive the add-on payment. The ICD-10 Coordination and Maintenance (C&M) Committee is responsible for approving coding changes, developing errata, addenda, and other modifications. Requests for coding changes are submitted to the committee. If any coding changes are necessary to distinctly identify your technology by ICD-10-CM diagnosis and/or ICD-10-PCS procedure code(s), you MUST separately contact the ICD-10 C&M Committee to submit a code request. For more details, including the deadlines to submit code requests, refer to the New/Revised ICD-10-PCS Procedure Codes Requests and ICD-10 Coordination and Maintenance Committee for diagnosis code requests.</i>
Coding and MS-DRGs	ICD-10-CM Diagnosis Codes	No change	No change	1. ICD-10-CM Diagnosis Codes a) List the ICD-10-CM diagnosis codes, with titles, that may currently be used to identify

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> List the ICD-10-CM diagnosis codes, with titles, that may currently be used to identify the indication/proposed indication relevant to the application under the ICD-10-CM coding system: <ul style="list-style-type: none"> Note: Please use standard formatting for ICD-10-CM/PCS codes in your response. Standard formatting for ICD-10-CM/PCS codes has the descriptor following the code in parentheses, and capitalizes only the first letter of the descriptor. Example: I21.A1 (Myocardial infarction type 2) Explain why these diagnosis code(s) were included and whether they are specific to the indication listed under the Breakthrough Device/QIDP/LPAD designation. 			<p>the indication/proposed indication relevant to the application under the ICD-10-CM coding system: Note: Please use standard formatting for ICD-10-CM/PCS codes in your response. Standard formatting for ICD-10-CM/PCS codes has the descriptor following the code in parentheses, and capitalizes only the first letter of the descriptor. Example: I21.A1 (Myocardial infarction type 2)</p> <p>b) Explain why these diagnosis code(s) were included and whether they are specific to the indication listed under the Breakthrough Device/QIDP/LPAD designation.</p>
Coding and MS-DRGs	<p>ICD-10-PCS Procedure Codes</p> <ul style="list-style-type: none"> List the procedure codes that may currently be used to identify your technology under the ICD-10-PCS coding system. <ul style="list-style-type: none"> Note: Please use standard formatting for ICD-10-CM/PCS codes in your response. Standard formatting for ICD-10-CM/PCS codes has the descriptor following the code in parentheses, and capitalizes only the first letter of the descriptor. Example: I21.A1 (Myocardial infarction type 2) Do these codes uniquely identify your technology under the ICD-10-PCS coding system? (Yes/No) Please explain. <ul style="list-style-type: none"> IF NO: Have you submitted or will you be submitting an application for a unique ICD-10-PCS code? 	Language has been clarified, and an accurate example was provided.	No change	<p>2. ICD-10-PCS Procedure Codes</p> <p>a) List the ICD-10-PCS procedure codes, with titles, that may currently be used to identify your technology under the ICD-10-PCS coding system. Note: Please use standard formatting for ICD-10-CM/PCS codes in your response. Standard formatting for ICD-10-CM/PCS codes has the descriptor following the code in parentheses, and capitalizes only the first letter of the descriptor. Example: 047KOZZ (Dilation of right femoral artery, open approach)</p> <p>b) Do these codes uniquely identify your technology under the ICD-10-PCS coding system? (Yes/No) Please explain. <ul style="list-style-type: none"> IF NO: Have you submitted or will you be submitting an application for a unique ICD-10-PCS code? </p>
Coding and MS-DRGs	<p>Existing technologies using ICD-10-CM/ICD-10-PCS - List existing technologies that use the same ICD-10-PCS codes or combination of the ICD-10-CM/PCS codes.</p> <p>ICD-10 C&M Committee Request</p> <ul style="list-style-type: none"> Does this technology have an existing request pending with the ICD-10 C&M Committee for a new code? (Yes/No) Explain the reason for your answer above, and any details you have about status of requests with the ICD-10 C&M Committee, if applicable. 	Addition of “a” for proper grammar.	No change	<p>3. Existing technologies using ICD-10-CM/ICD-10-PCS - List existing technologies that use the same ICD-10-PCS codes or a combination of the ICD-10-CM/PCS codes.</p> <p>4. ICD-10 C&M Committee Request</p> <p>a) Does this technology have an existing request pending with the ICD-10 C&M Committee for a new code? (Yes/No)</p> <p>b) Explain the reason for your answer above, and any details you have about status of requests with the ICD-10 C&M Committee, if applicable.</p>
Coding and MS-DRGs	<p>MS-DRGs</p> <p>Under the MS-DRG grouper, list all of the MS-DRGs that the technology would currently map to based on the indication (diagnosis) that is the subject of this NTAP application. Note: Please refer to the latest version of the ICD-10 MS-DRGs list on the <u>MS-DRG Webpage</u> for the current list of MS-DRGs and titles.</p>	Date is updated annually.	No change	<p>5. MS-DRGs</p> <p>a) Under the MS-DRG grouper, list all of the MS-DRGs that the technology would currently map to based on the indication (diagnosis) that is the subject of this NTAP application. Note: Please refer to the latest version of the ICD-10 MS-DRGs list on the <u>MS-DRG Webpage</u> for the current list of MS-DRGs and titles.</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p><i>Note: Please use standard formatting for MS-DRGs in your response. Standard formatting for MS-DRGs has the descriptor following the MS-DRG number in parentheses, and capitalizes the first letter of each word, except for common words like “and,” “with,” etc. Example: 004 (Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face Mouth and Neck without Major O.R. Procedures).</i></p> <ul style="list-style-type: none"> Comments related to the MS-DRGs listed above (optional) Have you made, or do you anticipate making, a request to map to a new or different MS-DRG(s) for the upcoming Fiscal Year 2025? (Yes/No) IF YES, please provide details 			<p><i>Note: Please use standard formatting for MS-DRGs in your response. Standard formatting for MS-DRGs has the descriptor following the MS-DRG number in parentheses, and capitalizes the first letter of each word, except for common words like “and,” “with,” etc. Example: 004 (Tracheostomy with MV >96 Hours or Principal Diagnosis Except Face Mouth and Neck without Major O.R. Procedures).</i></p> <ul style="list-style-type: none"> Comments related to the MS-DRGs listed above (optional) Have you made, or do you anticipate making, a request to map to a new or different MS-DRG(s) for the upcoming Fiscal Year 2027? (Yes/No) IF YES, please provide details
<p>Newness Criterion (only displays for traditional applications)</p>	<p><u>Newness Criterion</u> Current treatments for the disease or condition that this technology treats or diagnoses</p> <ul style="list-style-type: none"> Are there any other treatments for the disease or condition that this technology treats or diagnoses? (Yes/No) Briefly describe current treatments for the disease or condition. <p>Substantial Similarity Criteria <i>Info: To qualify for a new technology add-on payment, the technology or service must not be reflected in the data used to establish the Medicare-Severity Diagnosis Related Groups (MS-DRGs). CMS has established three substantial similarity criteria to determine if a technology is similar to an existing technology. (Refer to 70 FR 47351 through 47352 and 74 FR 43813 through 43814 for additional details.)</i></p> <p><i>Note: A technology can be considered “new” as long as one of the three criteria are NOT met.</i></p> <ul style="list-style-type: none"> Does the technology use the same or a similar mechanism of action when compared to existing technology to achieve a therapeutic outcome? (Yes/No) <ul style="list-style-type: none"> Explain why or why not? Has the technology been assigned to the same MS-DRG when compared to an existing technology to achieve a therapeutic outcome? (Yes/No) <ul style="list-style-type: none"> Explain why or why not? Does the use of the technology involve treatment of the same or similar type of disease and patient population when compared to an existing technology? (Yes/No) <ul style="list-style-type: none"> Explain why or why not? 	<p>‘Yes’ answers have clarifying language to help applicants understand the nature of a ‘Yes’ response to these questions.</p>	<p>No change</p>	<p><u>F. Newness Criterion</u></p> <p>1. Current treatments for the disease or condition that this technology treats or diagnoses</p> <ol style="list-style-type: none"> Are there any other treatments for the disease or condition that this technology treats or diagnoses? (Yes/No) Briefly describe current treatments for the disease or condition. <p>2. Substantial Similarity Criteria <i>Info: To qualify for a new technology add-on payment, the technology or service must not be reflected in the data used to establish the Medicare-Severity Diagnosis Related Groups (MS-DRGs). CMS has established three substantial similarity criteria to determine if a technology is similar to an existing technology. (Refer to 70 FR 47351 through 47352 and 74 FR 43813 through 43814 for additional details.)</i></p> <p><i>Note: A technology can be considered “new” as long as one of the three criteria are NOT met.</i></p> <ul style="list-style-type: none"> Does the technology use the same or a similar mechanism of action when compared to existing technology to achieve a therapeutic outcome? (Yes, the technology does not use a different mechanism of action when compared to existing technology to achieve a therapeutic outcome. /No) <ul style="list-style-type: none"> Explain why not? Has the technology been assigned to the same MS-DRG when compared to an existing technology to achieve a therapeutic outcome? (Yes, use of the technology is not expected to change the MS-DRG assignment. /No) <ul style="list-style-type: none"> Explain why not? Does the use of the technology involve treatment of the same or similar type of disease and patient population when compared to an existing technology? (Yes, the use of the technology does not involve treatment of a different type of disease or patient population compared to existing technologies. /No) <ul style="list-style-type: none"> Explain why not?

Application Section	Application Language	Modifications	Burden	Revised Application Language
Newness Criterion <i>(only displays for traditional applications)</i>	<p>Newness Criterion Summary: Please briefly summarize your previous responses regarding how the technology meets the newness criterion overall.</p> <p>Upload files related to the newness criterion as needed (optional)</p>	<p>Language was edited for clarity, and a note was added to indicate that attachments here are not included in the public posting, so applicants should respond accordingly.</p>	<p>No change</p>	<p>3. Newness Criterion Summary</p> <p>a) Please briefly summarize your responses to the previous slide regarding how the technology meets the newness criterion overall.</p> <p>b) Upload files related to the newness criterion as needed (optional) <i>Please note that attachments uploaded in this section will not be included in the public posting. Please avoid referring to any attachments in the responses provided in this section. If using references, please use in-text citations rather than footnote numbering.</i></p>
<u>Cost and Volume</u>	<p>Cost and Volume <i>Info: The information in this section will not be included in the public posting but may be included in the proposed and final rules.</i></p> <p>Technology Cost</p> <ul style="list-style-type: none"> What is the current or anticipated cost of this technology to the hospital per inpatient stay? <i>Note: The cost of the technology will only be included in the final rule (for applications approved for NTAP).</i> How was the total cost per inpatient stay determined? Please include all relevant details and calculations to explain how the cost was determined. <i>Note: For devices, include the cost per unit and the average number of units per inpatient stay or for technologies sold on a subscription basis, an explanation of how the cost per case is calculated, including the list price of the technology and utilization across subscribers. For drugs, include the cost per unit/vial as well as the average dosage and number of vials per inpatient stay (whole vials if single-use) and/or units per patient (ml/kg/hr). Please provide specific details about how that average was determined (e.g., how the drug is sold (such as x vials per box), variables in the Medicare population that effects the dosage administration (body weight, disease progression, etc.), whether and how the average is weighted based on those variables, etc.).</i> Indicate if this is a device: Yes/No <i>If this is a device, you will be asked to provide a breakdown of the cost of each component in the next question.</i> <ul style="list-style-type: none"> Upload files or materials that support the cost of the technology and how 	<p>Added a comma to improve grammar.</p>	<p>No change</p>	<p>G. Cost and Volume <i>Info: The information in this section will not be included in the public posting but may be included in the proposed and final rules.</i></p> <p>1. Technology Cost</p> <ul style="list-style-type: none"> What is the current or anticipated cost of this technology to the hospital, per inpatient stay? <i>Note: The cost of the technology will only be included in the final rule (for applications approved for NTAP).</i> How was the total cost per inpatient stay determined? Please include all relevant details and calculations to explain how the cost was determined. <i>Note: For devices, include the cost per unit and the average number of units per inpatient stay or for technologies sold on a subscription basis, an explanation of how the cost per case is calculated, including the list price of the technology and utilization across subscribers. For drugs, include the cost per unit/vial as well as the average dosage and number of vials per inpatient stay (whole vials if single-use) and/or units per patient (ml/kg/hr). Please provide specific details about how that average was determined (e.g., how the drug is sold (such as x vials per box), variables in the Medicare population that effects the dosage administration (body weight, disease progression, etc.), whether and how the average is weighted based on those variables, etc.).</i> Indicate if this is a device: Yes/No <i>If this is a device, you will be asked to provide a breakdown of the cost of each component in the next question.</i> <ul style="list-style-type: none"> Upload files or materials that support the cost of the technology and how it was calculated (optional)

Application Section	Application Language	Modifications	Burden	Revised Application Language
	it was calculated (optional)			
Cost and Volume	<p>Cost Breakdown (for devices)</p> <ul style="list-style-type: none"> o <i>Info: Include a breakdown of the cost of the device components used in the per inpatient stay calculation (ie, relevant to the NTAP payment amount), clearly showing which components are the "new" ones. Note: Capital costs are not included in new technology add-on payments under the IPPS. (Refer to 72 FR 47307-47308 for further details.)</i> Provide a breakdown of how the cost of the technology is calculated and identify if any components are capital costs. For each component, include the following: <ul style="list-style-type: none"> • Name of Component • Type of Cost (capital vs operating) • Component Cost • Is this component new? (Yes/No) o You may provide comments regarding the cost breakdown here (optional) 	Very minor correction to change “ie” to “i.e.”	No change	<p>2. Cost Breakdown (for devices)</p> <p><i>Info: Include a breakdown of the cost of the device components used in the per inpatient stay calculation (i.e., relevant to the NTAP payment amount), clearly showing which components are the "new" ones. Note: Capital costs are not included in new technology add-on payments under the IPPS. (Refer to 72 FR 47307-47308 for further details.)</i></p> <ul style="list-style-type: none"> o Provide a breakdown of how the cost of the technology is calculated and identify if any components are capital costs. For each component, include the following: <ul style="list-style-type: none"> • Name of Component • Type of Cost (capital vs operating) • Component Cost • Is this component new? (Yes/No) o You may provide comments regarding the cost breakdown here (optional)
Cost and Volume	<p>Volume</p> <p><i>Info: The information in this section will not be included in the public posting but will be included in the final rule (for technologies approved for NTAP). Note: The volume estimates should be based on the actual or projected sales of your technology, not the total population eligible for the technology. Current Fiscal Year: (10/01/2023 - 09/30/2024) Upcoming Fiscal Year: (10/01/2024 - 09/30/2025)</i></p> <ul style="list-style-type: none"> • What is the anticipated inpatient Medicare volume of this technology for the current and upcoming Fiscal Year? <ul style="list-style-type: none"> o Current Fiscal Year Anticipated Inpatient Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. o Upcoming Fiscal Year Anticipated Inpatient Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. • What is the anticipated inpatient non-Medicare volume of this technology for the current and upcoming Fiscal Year? <ul style="list-style-type: none"> o Current Fiscal Year Anticipated Inpatient Non-Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. o Upcoming Fiscal Year Anticipated Inpatient Non-Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. 	Dates are updated annually. Edit made to “Info” note, changing ‘section’ to ‘question’ to clarify the scope of the note.	No change	<p>3. Volume</p> <p><i>Info: The information in this question will not be included in the public posting but will be included in the final rule (for technologies approved for NTAP). Note: The volume estimates should be based on the actual or projected sales of your technology, not the total population eligible for the technology. Current Fiscal Year: (10/01/2025 - 09/30/2026) Upcoming Fiscal Year: (10/01/2026 - 09/30/2027)</i></p> <ul style="list-style-type: none"> • What is the anticipated inpatient Medicare volume of this technology for the current and upcoming Fiscal Year? <ul style="list-style-type: none"> o Current Fiscal Year Anticipated Inpatient Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. o Upcoming Fiscal Year Anticipated Inpatient Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. • What is the anticipated inpatient non-Medicare volume of this technology for the current and upcoming Fiscal Year? <ul style="list-style-type: none"> o Current Fiscal Year Anticipated Inpatient Non-Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate. o Upcoming Fiscal Year Anticipated Inpatient Non-Medicare Volume <ul style="list-style-type: none"> ▪ Please describe how you arrived at this estimate.

Application Section	Application Language	Modifications	Burden	Revised Application Language
Cost Criterion	<p>Cost Criterion <i>Info: Information in this section (G) will not be included in the public posting, except for the NTAP Cost Criterion Codes and MS-DRGs worksheet. The information in this section may be included in the proposed and final rules. Please note that the numerical value of any charges in this section will not be made public, with the exception of column S (Final Inflated Case Weighted Standardized Charge Per Case).</i></p>	Updated to reflect updates in the public posting process, which now includes certain details that had previously been shared in the application summaries (within the NPRM and final rules).	No change	<p>G. Cost Criterion <i>Info: The information in this section (G) will be included in the public application posting, except for the NTAP Cost Analysis spreadsheet. However, information provided in the spreadsheet may be included in the proposed and final rules. In addition, the numerical value of any charges in this section will not be made public, with the exception of the Case Weighted Threshold (Column E) and the Final Inflated Case Weighted Standardized Charge Per Case (Column S).</i></p>
Cost Criterion	<p>Click here for guidance about the cost criterion.</p> <p>Cost Analysis <u>Download Appendix A for an explanation of how to standardize charges per case if multiple MS-DRGs are affected by the technology.</u></p> <ul style="list-style-type: none"> ▪ Step 1: Download FY2025 NTAP Cost Analysis spreadsheet.xlsx Using the table as demonstrated in the spreadsheet as a template, show how the standardized charge per case (if applicable, case weighted) exceeds the threshold for the cost criterion. Please be sure the formulas are retained in the cells, when using the spreadsheet. You may add additional tabs for additional analyses or to provide supporting data. ▪ Step 2: Upload the completed Cost Analysis Spreadsheet. ▪ Step 3: Does the final inflated average case-weighted standardized charge per case exceed the average case-weighted (if applicable) threshold for the cost criterion? (Yes/No) <ul style="list-style-type: none"> ○ Comments (optional) 	We’ve made minor edits to reference another location where the NTAP Cost Analysis spreadsheet can also be downloaded, and to change wording from “Download” to “See” for Appendix A. We’ve also added a note, to inform applicants that this sheet won’t be posted online.	No change	<p>1. Cost Criterion Click here for guidance about the cost criterion. <u>See Appendix A for an explanation of how to standardize charges per case if multiple MS-DRGs are affected by the technology.</u></p> <ul style="list-style-type: none"> a) Step 1: Download the FY2027 NTAP Cost Analysis spreadsheet.xlsx(available for download on the CMS webpage). Using the table as demonstrated in the spreadsheet as a template, show how the standardized charge per case (if applicable, case weighted) exceeds the threshold for the cost criterion. Please be sure the formulas are retained in the cells when using the spreadsheet. You may add additional tabs for additional analyses or to provide supporting data. b) Step 2: Upload the completed Cost Analysis Spreadsheet. <i>Note: This spreadsheet will not be included in the public application posting, but information from this spreadsheet may be included in the proposed and final rules.</i> c) Step 3: Does the final inflated average case-weighted standardized charge per case exceed the average case-weighted (if applicable) threshold for the cost criterion? (Yes/No) <ul style="list-style-type: none"> ○ Comments (optional)
Cost Criterion	<p>Cost Analysis Methodology With regard to the cost analysis spreadsheet, please detail the ICD-10-PCS/CM codes and MS-DRGs used to identify cases in your cost analysis/analyses.</p> <ul style="list-style-type: none"> • Step 1: Download the NTAP Cost Criterion Codes and MS-DRGs spreadsheet and complete the tables as demonstrated in the spreadsheet. • Step 2: Upload the completed “NTAP Cost Criterion Codes and MS-DRGs” spreadsheet. <i>This spreadsheet will be included in the public application posting, and information from this spreadsheet may be included in the proposed and final rules.</i> • Comments (optional) 	Because we say that this section is included, with exceptions, we no longer need to call this individual item out, as it’s included in the posting. Commentary deleted.	No change	<p>Cost Analysis Methodology 2. With regard to the cost analysis spreadsheet, please detail the ICD-10-PCS/CM codes and MS-DRGs used to identify cases in your cost analysis/analyses.</p> <ul style="list-style-type: none"> • Step 1: Download the NTAP Cost Criterion Codes and MS-DRGs spreadsheet and complete the tables as demonstrated in the spreadsheet. • Step 2: Upload the completed “NTAP Cost Criterion Codes and MS-DRGs” spreadsheet. • Comments (optional)

Application Section	Application Language	Modifications	Burden	Revised Application Language
Cost Criterion	<p>Please provide the type of source data and year that was used to identify cases (such as “FY 2022 MedPAR” or “100% sample FY 2022 SAF”). If you did not use the most recently available claims data or if you used other types of source data, please also explain why. <i>Note: The most recent claims data for the upcoming application year would be 3 years prior (for example, for FY 2025 applications, the most recent claims data would be from FY 2022).</i></p>	<p>Years are updated (throughout) each successive cycle. No other changes.</p>	<p>No change</p>	<p>3. Please provide the type of source data and year that was used to identify cases (such as “FY 2024 MedPAR file” or “100% sample FY 2024 SAF”). If you did not use the most recently available claims data or if you used other types of source data, please also explain why. <i>Note: The most recent claims data for the upcoming application year would be 3 years prior (for example, for FY 2027 applications, the most recent claims data would be from FY 2024).</i></p>
Cost Criterion	<p>Use the following questions A through S (which correspond to columns A through S of the cost analysis spreadsheet) to explain in detail how each column was completed, step-by-step.</p> <ul style="list-style-type: none"> • A. MS-DRG Explain how these MS-DRGs were determined, including any differences between multiple analyses if applicable. Please also discuss relevant decision points in choosing to include/exclude ICD-10-PCS/CM codes for identifying cases. If there are any other inclusion/exclusion criteria please describe them here as well. • B. Cases <i>Note: In compliance with the CMS data use agreement, the aggregate amount of cases listed for each MS-DRG in the table must indicate a minimum of 11; applicants should impute a value of 11 for any MS-DRG included with a number under 11.</i> • C. Case Weighted Amount • D. Threshold <i>Note: Please confirm the thresholds used were from the prior year’s final rule/correction notice. For example: for FY 2025 applications, the thresholds from the FY 2024 final rule (or correction notice, if applicable) should be used.</i> • E. Case Weighted Threshold • F. Average Charge Per Case (Unstandardized with No Case Weight) • G. Average Charge Per Case (Unstandardized with Case Weight) • H. Charges Removed for the Prior Technology or Technology Being Replaced <i>Note: Please also discuss the assumptions behind removing (or not removing) charges for prior technologies. For example, if a technology is replacing the implantation of a different device, explain how the removal of charges for the previous device was determined; do not remove related charges such as operating room (OR) and/or intensive care unit (ICU) charges in this column.</i> • I. Related Charges Removed for the Prior Technology or Technology Being Replaced 	<p>Dates updated annually. No other change.</p>	<p>No change</p>	<p>4. Use the following questions A through S (which correspond to columns A through S of the cost analysis spreadsheet) to explain in detail how each column was completed, step-by-step.</p> <ul style="list-style-type: none"> • A. MS-DRG Explain how these MS-DRGs were determined, including any differences between multiple analyses if applicable. Please also discuss relevant decision points in choosing to include/exclude ICD-10-PCS/CM codes for identifying cases. If there are any other inclusion/exclusion criteria please describe them here as well. • B. Cases <i>Note: In compliance with the CMS data use agreement, the aggregate amount of cases listed for each MS-DRG in the table must indicate a minimum of 11; applicants should impute a value of 11 for any MS-DRG included with a number under 11.</i> • C. Case Weighted Amount • D. Threshold <i>Note: Please confirm the thresholds used were from the prior year’s final rule/correction notice. For example: for FY 2027 applications, the thresholds from the FY 2026 final rule (or correction notice, if applicable) should be used.</i> • E. Case Weighted Threshold • F. Average Charge Per Case (Unstandardized with No Case Weight) • G. Average Charge Per Case (Unstandardized with Case Weight) • H. Charges Removed for the Prior Technology or Technology Being Replaced <i>Note: Please also discuss the assumptions behind removing (or not removing) charges for prior technologies. For example, if a technology is replacing the implantation of a different device, explain how the removal of charges for the previous device was determined; do not remove related charges such as operating room (OR) and/or intensive care unit (ICU) charges in this column.</i> • I. Related Charges Removed for the Prior Technology or Technology Being Replaced <i>Note: Please also discuss the assumptions behind removing (or not removing) related charges for prior technologies. For example, if the technology is replacing the implantation of a different device and requires less or more OR time and ICU days, explain how the removal of related charges such as OR/ICU charges were determined.</i> • J. Adjusted Average Charge Per Case (Unstandardized with No Case Weight) • K. Adjusted Average Charge Per Case (Unstandardized with Case Weight) • L. Average Standardized Charge Per Case

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> Note: Please also discuss the assumptions behind removing (or not removing) related charges for prior technologies. For example, if the technology is replacing the implantation of a different device and requires less or more OR time and ICU days, explain how the removal of related charges such as OR/ICU charges were determined. J. Adjusted Average Charge Per Case (Unstandardized with No Case Weight) K. Adjusted Average Charge Per Case (Unstandardized with Case Weight) L. Average Standardized Charge Per Case Note: Please include sources for provider-specific factors used to standardize charges (for example, use of the FY 2022 final rule/correction notice impact file). M. Average Standardized Charge Per Case with Case Weight N. Inflation Factor Note: The inflation factor should be aligned with the year of claims data used, and the year for which the applicant is applying for NTAP. For example, when using FY 2022 MedPAR data and applying for FY 2025 NTAP, a three-year inflation factor would be appropriate. O. Inflated Average Standardized Charges Per Case P. Charges Added for the New Technology Please explain how the current and/or anticipated charges for the technology by the hospital, per patient, were determined. Please confirm that the most recent national cost center CCRs (listed in the cost analysis spreadsheet) were used to convert cost to charges, if applicable. Note: The charges here should be only based on direct costs of the drug/device itself, and not related costs such as OR/ICU charges. Q. Related Charges Added for the New Technology Note: The charges here should be only based on indirect costs related to use of the drug/device, such as OR/ICU charges. Please also discuss the assumptions behind adding (or not adding) related charges for the new technology. R. Final Average Inflated Standardized Charge Per Case S. Final Inflated Case Weighted Standardized Charge Per Case 			<p>Note: Please include sources for provider-specific factors used to standardize charges (for example, use of the FY 2024 final rule/correction notice impact file).</p> <ul style="list-style-type: none"> M. Average Standardized Charge Per Case with Case Weight N. Inflation Factor Note: The inflation factor should be aligned with the year of claims data used, and the year for which the applicant is applying for NTAP. For example, when using FY 2024 MedPAR file data and applying for FY 2027 NTAP, a three-year inflation factor would be appropriate. O. Inflated Average Standardized Charges Per Case P. Charges Added for the New Technology Please explain how the current and/or anticipated charges for the technology by the hospital, per patient, were determined. Please confirm that the most recent national cost center CCRs (listed in the cost analysis spreadsheet) were used to convert cost to charges, if applicable. Note: The charges here should be only based on direct costs of the drug/device itself, and not related costs such as OR/ICU charges. Q. Related Charges Added to the New Technology Note: The charges here should be only based on indirect costs related to use of the drug/device, such as OR/ICU charges. Please also discuss the assumptions behind adding (or not adding) related charges for the new technology. R. Final Average Inflated Standardized Charge Per Case S. Final Inflated Case Weighted Standardized Charge Per Case
Substantial Clinical Improvement (displays only for traditional applications)	<p>Substantial Clinical Improvement Info: A summary on the substantial clinical improvement (SCI) criterion can be found in Appendix B. Additional information on the SCI criterion can be found in the September 7, 2001 Federal Register (66 FR 46913-14), the FY 2010 IPPS Final Rule (74 FR 43808-43823) and the FY 2020 IPPS Final Rule (84 FR 42288-42292). Additionally, the annual IPPS final rule includes CMS' decision-making processes for each application.</p>	<p>We made minor text revisions for accuracy, consistency, and clarity, and added a note to help applicants stay within compliance of application limitations.</p>	<p>No change</p>	<p>H. Substantial Clinical Improvement Info: A summary on the substantial clinical improvement (SCI) criterion can be found in Appendix B. Additional information on the SCI criterion can be found in the September 7, 2001 Federal Register (66 FR 46913-14), the FY 2010 IPPS/LTCH PPS Final Rule (74 FR 43808-43823) and the FY 2020 IPPS/LTCH PPS Final Rule (84 FR 42288-42292). Additionally, the annual IPPS final rule includes CMS's decision-making processes for each application.</p> <p>Overview of the SCI Criterion</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p>Overview of the SCI Criterion <i>CMS uses the following in its evaluation of SCI for the purposes of the NTAP:</i></p> <ol style="list-style-type: none"> <i>1. The new medical service or technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</i> <i>2. The new medical service or technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods. There must also be evidence that the use of the new medical service or technology to make a diagnosis affects the management of the patient.</i> <i>3. The use of the new medical service or technology significantly improves clinical outcomes relative to services or technologies previously available.</i> <p><i>A technology must demonstrate that it meets at least one of these three in order to be eligible for NTAP.</i></p> <p>Overview of the SCI Section <i>As you navigate through the Substantial Clinical Improvement section, you will be asked how the technology meets the SCI criterion. For each assertion made, you will be asked to explain why you believe the technology meets the SCI criterion. Each reason the technology meets the SCI criterion will need to be added as a separate claim, using supporting data as applicable.</i></p> <ul style="list-style-type: none"> <i>• You will be able to enter one or more claims (i.e., reasons) for each assertion made.</i> <i>• Each claim for an assertion must be added individually.</i> <i>• If you have evidence to support a claim, you will be able to provide one or more pieces of supporting evidence for each claim.</i> <i>• For each piece of evidence uploaded, you will be asked to describe the upload and summarize details related to the upload, such as the reason for inclusion/relevance to the claim, citation, summary of the data source, and results from the study that support the claim.</i> <i>• CMS may include attachments provided in this section as part of the public application posting. If any attachments are uploaded that cannot be made public due to copyright restrictions or other reasons, you must indicate that by selecting the checkbox under the upload.</i> <i>• Once you provide responses for each of the SCI Criterion questions (including supporting evidence if applicable), you will be asked to provide a brief summary of these responses to explain overall why you believe the technology demonstrates a substantial clinical improvement over existing technologies.</i> 			<p><i>CMS uses the following in its evaluation of SCI for the purposes of the NTAP:</i></p> <ol style="list-style-type: none"> <i>1. The new medical service or technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</i> <i>2. The new medical service or technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods. There must also be evidence that the use of the new medical service or technology to make a diagnosis affects the management of the patient.</i> <i>3. The use of the new medical service or technology significantly improves clinical outcomes relative to services or technologies previously available.</i> <p><i>A technology must demonstrate that it meets at least one of these three sub-criteria in order to be eligible for NTAP.</i></p> <p>Overview of the SCI Section <i>As you navigate through the Substantial Clinical Improvement section, you will be asked which of the sub-criteria you believe the technology meets in order to demonstrate how the technology meets the SCI criterion.</i></p> <ul style="list-style-type: none"> <i>• You will be able to enter one or more claims (i.e., reasons) under each sub-criterion.</i> <i>• Each claim under a sub-criterion must be added individually.</i> <i>• Provide one or more pieces of supporting evidence for each claim.</i> <i>• For each piece of evidence uploaded, you will be asked to describe the upload and summarize details related to the upload, such as the reason for inclusion/relevance to the claim, citation, summary of the data source, and results from the study that support the claim.</i> <i>• CMS may include attachments provided in this section as part of the public application posting. If any attachments are uploaded that cannot be made public due to copyright restrictions or other reasons, you must indicate that by selecting the checkbox under the upload.</i> <i>• Once you provide responses for each of the SCI sub-criteria questions (including supporting evidence if applicable), you will be asked to provide a brief summary of these responses to explain overall why you believe the technology demonstrates a substantial clinical improvement over existing technologies.</i> <p><i>Note: Responses to the questions should be limited to the text boxes provided and should not extend into supplemental attachments.</i></p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
Substantial Clinical Improvement <i>(displays only for traditional applications)</i>	<p>Does the new medical service or technology offer a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments? (Y/N)</p> <p>IF YES:</p> <p>You stated that the new medical service or technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</p> <p>Please provide an explanation for this assertion using supporting data. Add each reason as a separate claim.</p> <p>(i) Add Claim - Claim Title</p> <p>(ii) Please provide a full explanation</p> <p>(iii) Add Supporting Evidence, if applicable</p> <p>a. Select an existing file or upload a new one</p> <p>b. Upload file and answer the following questions related to each upload:</p> <p>i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting.</p> <p>ii. Title of the supporting evidence</p> <p>iii. Data Source category (choose one)</p> <ul style="list-style-type: none"> • Published, peer, reviewed studies using technology • Unpublished studies, abstracts, or presentations using technology • Other data submissions using technology • Data submissions as background (does not directly assess the technology) <p>iv. Evidence Type (choose one)</p> <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics,</i></p>	<p>We've made minor text revisions for clarity (to help the applicant better understand the answer they're selecting) and grammar (space, addition of 'the'). We're also implementing a new classification of evidence type, to help clarify the nature of the data source being provided by the applicant. In addition, we've added a note for process clarity.</p>	<p>No change</p>	<p>1. Does the new medical service or technology offer a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments? (Y/N)</p> <p>IF YES:</p> <p>You stated that the new medical service or technology offers a treatment option for a patient population unresponsive to, or ineligible for, currently available treatments.</p> <p>Please explain which patients have no other treatment options, and provide supporting data.</p> <p>(i) Add Claim - Claim Title</p> <p>(ii) Please provide a full explanation</p> <p>(iii) Add Supporting Evidence, if applicable</p> <p>a. Select an existing file or upload a new one</p> <p><i>Note: Only one attachment may be entered at a time. You may select or upload additional supporting evidence for this claim after clicking "Save."</i></p> <p>b. Upload file and answer the following questions related to each upload:</p> <p>i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting.</p> <p>ii. Title of the supporting evidence</p> <p>iii. Data Source category (choose one)</p> <ul style="list-style-type: none"> • Published studies using the technology • Unpublished studies using the technology • Studies demonstrating outcomes for a comparator technology • Background/Contextual <p>iv. Evidence Type (choose one)</p> <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics, inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <p>i. Reason for inclusion/relevance to the claim</p> <p>ii. What are the results/outcomes from this study that support this claim?</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<p><i>inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <ol style="list-style-type: none"> i. Reason for inclusion/relevance to claim ii. What are the results/outcomes from this study that support this claim? Please be sure to provide the specific statistic(s)/value(s) in your response. iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.) 			<p>Please be sure to provide the specific statistic(s)/value(s) in your response.</p> <p>iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.)</p>
<p>Substantial Clinical Improvement <i>(displays only for traditional applications)</i></p>	<p>▪ Does the new medical service or technology offer the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods? There must also be evidence that use of the new medical service or technology to make a diagnosis affects the management of the patient. (Y/N)</p> <p>IF YES:</p> <ol style="list-style-type: none"> (i) Add Claim - Claim Title (ii) Please provide a full explanation (iii) Add Supporting Evidence, if applicable <ol style="list-style-type: none"> a. Select an existing file or upload a new one b. Upload file and answer the following questions related to each upload: <ol style="list-style-type: none"> i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting. ii. Title of the supporting evidence iii. Data Source category (choose one) <ul style="list-style-type: none"> • Published, peer, reviewed studies using technology • Unpublished studies, abstracts, or presentations using technology • Other data submissions using technology • Data submissions as background (does not directly assess the technology) iv. Evidence Type (choose one) <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study 	<p>We've made text revisions for clarity (to help the applicant better understand the answer they're selecting and what is needed to support their claims). We also updated for proper grammar (space, addition of 'the'). We're implementing a new classification of evidence type, to help clarify the nature of the data source being provided by the applicant. In addition, we've added notes for process clarity.</p>	<p>No change</p>	<p>2. Does the new medical service or technology offer the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods? There must also be evidence that use of the new medical service or technology to make a diagnosis affects the management of the patient. (Y/N)</p> <p>IF YES:</p> <p>You stated that the new medical service or technology offers the ability to diagnose a medical condition in a patient population where that medical condition is currently undetectable or offers the ability to diagnose a medical condition earlier in a patient population than allowed by currently available methods and there must also be evidence that use of the new medical service or technology to make a diagnosis affects the management of the patient.</p> <p>Please include the medical condition and Medicare patient population relevant to this claim as well as the change in patient management in your explanation using supporting data. Add each reason as a separate claim.</p> <ol style="list-style-type: none"> (i) Add Claim - Claim Title (ii) Please provide a full explanation (iii) Add Supporting Evidence, if applicable <ol style="list-style-type: none"> a. Select an existing file or upload a new one Note: Only one attachment may be entered at a time. You may select or upload additional supporting evidence for this claim after clicking "Save." b. Upload file and answer the following questions related to each upload: <ol style="list-style-type: none"> i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting. ii. Title of the supporting evidence iii. Data Source category (choose one)

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics, inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <p>i. Reason for inclusion/relevance to claim</p> <p>ii. What are the results/outcomes from this study that support this claim? Please be sure to provide the specific statistic(s)/value(s) in your response.</p> <p>iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.)</p>			<ul style="list-style-type: none"> • Published studies using the technology • Unpublished studies using the technology • Studies demonstrating outcomes for a comparator technology • Background/Contextual <p>iv. Evidence Type (choose one)</p> <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics, inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <p>i. Reason for inclusion/relevance to the claim</p> <p>ii. What are the results/outcomes from this study that support this claim? Please be sure to provide the specific statistic(s)/value(s) in your response.</p> <p>iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.)</p>
Substantial Clinical Improvement <i>(displays only for traditional applications)</i>	<p>▪ Does the use of the new medical service or technology significantly improve clinical outcomes relative to services or technologies previously available? (Y/N)</p> <p>IF YES:</p> <p>(i) Add Claim - Claim Title</p> <p>(ii) Please provide a full explanation</p> <p>(iii) Add Supporting Evidence, if applicable</p> <p>a. Select an existing file or upload a new one</p> <p>b. Upload file and answer the following questions related to each upload:</p> <p>i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting.</p> <p>ii. Title of the supporting evidence</p> <p>iii. Data Source category (choose one)</p> <ul style="list-style-type: none"> • Published, peer, reviewed studies using technology 	<p>We've made minor text revisions for clarity (to help the applicant better understand the answer they're selecting and what is needed to support their claims). We also updated for proper grammar (space, addition of 'the'). We're implementing a new classification of evidence type, to help clarify the nature of the data source being provided by the applicant. In addition, we've added notes for process clarity.</p>	<p>No change</p>	<p>3. Does the use of the new medical service or technology significantly improve clinical outcomes relative to services or technologies previously available? (Y/N)</p> <p>IF YES:</p> <p>You stated that use of the new medical service or technology significantly improve clinical outcomes relative to services or technologies previously available.</p> <p>Please explain how the technology demonstrates improved outcomes compared to existing technologies using supporting data. Add each reason as a separate claim.</p> <p>(i) Add Claim - Claim Title</p> <p>(ii) Please provide a full explanation</p> <p>(iii) Add Supporting Evidence, if applicable</p> <p>a. Select an existing file or upload a new one</p> <p>Note: Only one attachment may be entered at a time. You may select or upload additional supporting evidence for this claim after clicking "Save."</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
	<ul style="list-style-type: none"> • Unpublished studies, abstracts, or presentations using technology • Other data submissions using technology • Data submissions as background (does not directly assess the technology) <p>iv. Evidence Type (choose one)</p> <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics, inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <p>i. Reason for inclusion/relevance to claim</p> <p>ii. What are the results/outcomes from this study that support this claim? Please be sure to provide the specific statistic(s)/value(s) in your response.</p> <p>iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.)</p>			<p>b. Upload file and answer the following questions related to each upload:</p> <p>i. <input type="checkbox"/> The applicant does not have the appropriate license or right to release this document to the public. If this box is checked, this document will not be included in the public posting.</p> <p>ii. Title of the supporting evidence</p> <p>iii. Data Source category (choose one)</p> <ul style="list-style-type: none"> • Published studies using the technology • Unpublished studies using the technology • Studies demonstrating outcomes for a comparator technology • Background/Contextual <p>iv. Evidence Type (choose one)</p> <ul style="list-style-type: none"> • Case-control Study • Case Reports and Case Series • Cohort Study • Cross-sectional Study • Meta-Analysis • Randomized Controlled Trial • Systematic Review • Other <p>v. Citation</p> <p>vi. Study summary: <i>Please clearly summarize the study in full, to include (at minimum) the purpose of the study, number of patients treated, study arms, demographics, inclusion/exclusion criteria, endpoints tested, and outcomes (specify if statistically significant).</i></p> <p>c. Please explain why this uploaded file was provided in support of this claim</p> <p>i. Reason for inclusion/relevance to the claim</p> <p>ii. What are the results/outcomes from this study that support this claim? Please be sure to provide the specific statistic(s)/value(s) in your response.</p> <p>iii. Provide the location of these results/outcomes (i.e. page number(s), paragraph, table number, etc., as applicable.)</p>
<p>Substantial Clinical Improvement <i>(displays only for traditional applications)</i></p>	<p>SCI Criterion Summary and Attestation</p> <ul style="list-style-type: none"> • Please briefly summarize your responses to this section regarding how the technology meets the substantial clinical improvement criterion overall. <p><input type="checkbox"/> I represent and warrant, on behalf of the applicant, that except for those documents for which I indicated otherwise, the applicant owns the copyright or otherwise has the appropriate license to make available all of the documents uploaded in this section to the public. I certify that I have been duly authorized to submit this representation on behalf of the applicant.</p>	No change	No change	<p>4. SCI Criterion Summary and Attestation</p> <p>a) Please briefly summarize your responses to this section regarding how the technology meets the substantial clinical improvement criterion overall.</p> <p>b) <input type="checkbox"/> I represent and warrant, on behalf of the applicant, that except for those documents for which I indicated otherwise, the applicant owns the copyright or otherwise has the appropriate license to make available all of the documents uploaded in this section to the public. I certify that I have been duly authorized to submit this representation on behalf of the applicant.</p>

Application Section	Application Language	Modifications	Burden	Revised Application Language
Summary	<p>Summary <i>Info: If there is any information that you wish to provide with your application that should not be posted publicly, it must only be added in the "Additional Application Information - CONFIDENTIAL" section below. Please note that we generally do not consider any information that cannot be made public when determining whether a technology meets the NTAP criteria.</i></p> <p>Additional Application Information – CONFIDENTIAL Do you have any information that you wish to provide as part of your application that should not be made public? Please note that the information in this section will not be considered when determining whether a technology meets the NTAP criteria and will not be made public. (Y/N) IF YES: a) Select section and corresponding information below (add more than one if desired): b) Confidential information about this section: <i>Note: Data provided in this section may become subject to disclosure where required by law. CMS will attempt, to the extent allowed by law, to keep this information protected from public view.</i> c) Upload any relevant files (optional)</p>	As is	No change	<p>I. Summary <i>Info: If there is any information that you wish to provide with your application that should not be posted publicly, it must only be added in the "Additional Application Information - CONFIDENTIAL" section below. Please note that we generally do not consider any information that cannot be made public when determining whether a technology meets the NTAP criteria.</i></p> <p>Additional Application Information – CONFIDENTIAL Do you have any information that you wish to provide as part of your application that should not be made public? Please note that the information in this section will not be considered when determining whether a technology meets the NTAP criteria and will not be made public. (Y/N) IF YES: a) Select section and corresponding information below (add more than one if desired): b) Confidential information about this section: <i>Note: Data provided in this section may become subject to disclosure where required by law. CMS will attempt, to the extent allowed by law, to keep this information protected from public view.</i> c) Upload any relevant files (optional)</p>